NEWS DETAIL

Notice Regarding Results and Completion of Acquisition of Treasury Shares

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President and CEO: NAKATOMI Kazuhide;) announces that we have acquired treasury shares as follows, in accordance with the provisions of Article 156 of the Companies Act, which is applied by replacing the terms pursuant to the provisions of Article 165, Paragraph 3 of the said Act.

We are also pleased to announce that the acquisition of treasury shares based on the resolution of the board of directors held on October 14, 2021 has been completed with the following acquisition.

1.Type of shares acquired:

2.Total number of shares acquired:

3.Total amount of value of shares acquired:

4.Acquisition period:

5.Method of acquisition:

Common share of the Company 2 million shares

8,041,487,000 yen

November 11, 2021 to January 13, 2022 Market purchase on the Tokyo Stock Exchange

(Reference information)

Resolutions at the board of directors held on October 14, 2021

1.

Type of shares to be acquired:

Common share of the Company

2.

Total number of shares that can be acquired: 2 million shares (upper limit)

 

 

(2.45% of total number of shares issued (excluding

 

 

treasury shares))

3.

Total amount of value of shares acquired:

12 billion yen (upper limit)

4.

Acquisition period:

October 15, 2021 to February 28, 2022